Single injection of intra-articular autologous protein solution in horses with acute interleukin-1B-induced synovitis decreases joint pathology scores.
Authors: Usimaki Alexandra, Ciamillo Sarah A, Barot Dhvani, Linardi Renata L, Engiles Julie B, Ortved Kyla F
Journal: Equine veterinary journal
Summary
# Editorial Summary: Autologous Protein Solution in Early Synovitis Autologous protein solution (APS) has demonstrated clinical benefits in equine osteoarthritis, yet opportunities remain to intervene earlier in the disease cascade—specifically during the synovitic phase that precedes established degenerative changes. Researchers at the University of Pennsylvania induced acute IL-1β-mediated synovitis in tarsocrural joints and administered a single intra-articular injection of APS (Pro-Stride®) to 12 horses 24 hours post-induction, with six untreated controls, tracking lameness, joint circumference, synovial fluid biomarkers (protein, nucleated cell count, IL-1β, TNF-α, IFN-γ, IL-6, IL-10, and PGE2), and histopathological changes over 14 days. Notably, whilst APS treatment failed to reduce lameness scores or joint swelling compared with controls, and produced no measurable differences in synovial fluid parameters including cytokine and prostaglandin concentrations, it did significantly improve both gross pathological appearance and synovial membrane histology scores—suggesting subclinical disease modification despite the absence of clinical improvement. The disconnect between tissue-level healing and functional/biochemical outcomes warrants cautious interpretation, particularly given the model's inherent limitations (induced rather than naturally occurring disease, individual variation in IL-1β response, and batch variability in APS composition). For practitioners, these findings suggest APS may offer structural benefits in early synovitis that warrant further investigation in clinical settings, though current evidence does not support its use primarily for acute lameness resolution at this stage of disease.
Read the full abstract on PubMed
Practical Takeaways
- •While APS did not improve lameness or clinical swelling in this acute synovitis model, histological improvements suggest potential value may not be captured by lameness exams alone; consider joint pathology rather than solely clinical signs when evaluating treatment response.
- •Single APS injection may modify tissue pathology in early synovitis, but timing (24 hours post-induction) and dosing protocols require further investigation before clinical recommendations can be made.
- •Individual horse variability in both inflammatory response and APS composition means treatment response is unpredictable; this study does not support routine APS use as a standard treatment for acute synovitis based on current evidence.
Key Findings
- •Single intra-articular APS injection did not reduce lameness or joint circumference compared to untreated controls in IL-1β-induced synovitis.
- •Synovial fluid parameters (protein, cell counts, cytokines, PGE2) showed no significant differences between APS-treated and control joints.
- •APS treatment significantly decreased gross pathology and synovial membrane histopathology scores, suggesting potential disease-modifying effects.
- •Study limitations included use of an induced model, inter-horse variability in IL-1β response, and variable APS constituent composition between individual horses.